Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Ravelli

Showing results (221-230 of 341) with videos related to

Pageof 35
Sort By:
Clinical Immunology (Orlando, Fla.)|August 29, 2021
Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD)Riccardo Papa, Marta Rusmini, Francesca Schena, et al.
Arthritis and Rheumatism|March 3, 2007
The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosisFrancesco Zulian, Patricia Woo, Balu H Athreya, et al.
Arthritis Care & Research|April 26, 2018
American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus ErythematosusHermine I Brunner, Michael Holland, Michael W Beresford, et al.
The Journal of Rheumatology|November 16, 2020
Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile DermatomyositisSilvia Rosina, Giulia C Varnier, Angela Pistorio, et al.
RMD Open|October 19, 2022
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseasesKastriot Kastrati, Daniel Aletaha, Gerd R Burmester, et al.
Arthritis Care & Research|May 13, 2017
Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic ArthritisGrant S Schulert, Francesca Minoia, John Bohnsack, et al.
Italian Journal of Pediatrics|January 26, 2021
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki diseaseAlessandra Marchesi, Donato Rigante, Rolando Cimaz, et al.
Arthritis and Rheumatism|April 1, 2009
Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort studyMaria Teresa Apaz, Claudia Saad-Magalhães, Angela Pistorio, et al.
Frontiers in Pediatrics|September 7, 2023
Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national studyFrancesco Licciardi, Carlotta Covizzi, Marta Dellepiane, et al.
Pediatric Rheumatology Online Journal|May 24, 2019
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patientsGabriella Giancane, Claudio Lavarello, Angela Pistorio, et al.
Pageof 35

Showing results (221-230 of 341) with videos related to

Sort By:
Pageof 35
Clinical Immunology (Orlando, Fla.)|August 29, 2021
Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD)Riccardo Papa, Marta Rusmini, Francesca Schena, et al.
Arthritis and Rheumatism|March 3, 2007
The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosisFrancesco Zulian, Patricia Woo, Balu H Athreya, et al.
Arthritis Care & Research|April 26, 2018
American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus ErythematosusHermine I Brunner, Michael Holland, Michael W Beresford, et al.
The Journal of Rheumatology|November 16, 2020
Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile DermatomyositisSilvia Rosina, Giulia C Varnier, Angela Pistorio, et al.
RMD Open|October 19, 2022
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseasesKastriot Kastrati, Daniel Aletaha, Gerd R Burmester, et al.
Arthritis Care & Research|May 13, 2017
Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic ArthritisGrant S Schulert, Francesca Minoia, John Bohnsack, et al.
Italian Journal of Pediatrics|January 26, 2021
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki diseaseAlessandra Marchesi, Donato Rigante, Rolando Cimaz, et al.
Arthritis and Rheumatism|April 1, 2009
Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort studyMaria Teresa Apaz, Claudia Saad-Magalhães, Angela Pistorio, et al.
Frontiers in Pediatrics|September 7, 2023
Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national studyFrancesco Licciardi, Carlotta Covizzi, Marta Dellepiane, et al.
Pediatric Rheumatology Online Journal|May 24, 2019
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patientsGabriella Giancane, Claudio Lavarello, Angela Pistorio, et al.
Pageof 35